Joflupaan (123i) Rotop (Ioflupane (123i))

Ioflupane binds selectively to presynaptic dopamine transporters (DAT) on dopaminergic neurons. After intravenous injection, the radiolabelled compound accumulates in brain regions with functional DAT, allowing SPECT scanners to produce images that reflect the density and distribution of these transporters, which are reduced in Parkinsonian conditions.

The prescribed dose of Joflupaan (Ioflupane) is determined by the treating physician or nuclear medicine specialist based on patient characteristics, imaging protocol, and regulatory guidelines. The healthcare provider will calculate the appropriate activity (in megabecquerels) and administer it intravenously under controlled conditions.

The safety of Ioflupane in pregnancy and lactation has not been fully established. It is generally avoided unless the diagnostic benefit outweighs potential risks to the fetus or infant. Clinicians should discuss possible alternatives and consider postponing the procedure if pregnancy is confirmed or if the patient is breastfeeding.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Joflupaan (Ioflupane) is a widely used DAT SPECT tracer with high affinity and favorable imaging characteristics. Compared with alternatives such as ^123I‑FP‑CIT (DaTscan), it offers comparable sensitivity for detecting dopaminergic deficits, but specific performance may vary based on imaging equipment, protocol, and regulatory approvals in different regions.

Joflupaan should be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. The product must be kept in its original container until use, and handling should follow radiopharmacy safety standards to maintain stability and ensure accurate dosing.

The drug is supplied as an injectable solution for intravenous administration. A qualified healthcare professional injects the calculated activity of Ioflupane into a peripheral vein, typically in a controlled nuclear medicine suite, followed by a waiting period before SPECT imaging is performed.

Serious risks include severe allergic reactions such as anaphylaxis, significant hypotension that may require medical intervention, and rare radiation‑induced tissue injury at the injection site. Patients should be monitored during and after administration, and emergency measures should be readily available.

Joflupaan is contraindicated in patients with known hypersensitivity to Ioflupane or any component of the formulation. It should also be avoided in individuals who have received other dopamine‑targeting radiotracers within a short interval, or in pregnant women unless the diagnostic benefit justifies potential fetal exposure.